Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.Thienamycins: Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.Cilastatin: A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.Carbapenems: A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.Anti-Bacterial Agents: Substances that reduce the growth or reproduction of BACTERIA.Microbial Sensitivity Tests: Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).beta-Lactamases: Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.Pseudomonas aeruginosa: A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.Ceftazidime: Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.Acinetobacter baumannii: A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics.Acinetobacter Infections: Infections with bacteria of the genus ACINETOBACTER.Drug Resistance, Microbial: The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).CyclopropanesAcinetobacter: A genus of gram-negative bacteria of the family MORAXELLACEAE, found in soil and water and of uncertain pathogenicity.Sulbactam: A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.Dipeptidases: EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.Gram-Negative Bacteria: Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method.Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.Bacteroides fragilis: Gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections.Lactams: Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.Drug Resistance, Multiple, Bacterial: The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).Drug Resistance, Bacterial: The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).Cephalosporins: A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.Klebsiella pneumoniae: Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans.Pseudomonas Infections: Infections with bacteria of the genus PSEUDOMONAS.Gram-Negative Bacterial Infections: Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.Bacteria, AnaerobicEnterobacteriaceae Infections: Infections with bacteria of the family ENTEROBACTERIACEAE.Enterobacteriaceae: A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)Penicillin-Binding Proteins: Bacterial proteins that share the property of binding irreversibly to PENICILLINS and other ANTIBACTERIAL AGENTS derived from LACTAMS. The penicillin-binding proteins are primarily enzymes involved in CELL WALL biosynthesis including MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; PEPTIDE SYNTHASES; TRANSPEPTIDASES; and HEXOSYLTRANSFERASES.Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.Klebsiella Infections: Infections with bacteria of the genus KLEBSIELLA.Porins: Porins are protein molecules that were originally found in the outer membrane of GRAM-NEGATIVE BACTERIA and that form multi-meric channels for the passive DIFFUSION of WATER; IONS; or other small molecules. Porins are present in bacterial CELL WALLS, as well as in plant, fungal, mammalian and other vertebrate CELL MEMBRANES and MITOCHONDRIAL MEMBRANES.Cross Infection: Any infection which a patient contracts in a health-care institution.Gram-Positive Bacteria: Bacteria which retain the crystal violet stain when treated by Gram's method.Muramoylpentapeptide Carboxypeptidase: Enzyme which catalyzes the peptide cross-linking of nascent CELL WALL; PEPTIDOGLYCAN.Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.Enterobacter cloacae: A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in water, sewage, soil, meat, hospital environments, and on the skin and in the intestinal tract of man and animals as a commensal.Nafcillin: A semi-synthetic antibiotic related to penicillin.CephalosporinaseDrug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Hexosyltransferases: Enzymes that catalyze the transfer of hexose groups. EC 2.4.1.-.Pneumonia, Bacterial: Inflammation of the lung parenchyma that is caused by bacterial infections.Anti-Infective Agents: Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.Peptidyl Transferases: Acyltransferases that use AMINO ACYL TRNA as the amino acid donor in formation of a peptide bond. There are ribosomal and non-ribosomal peptidyltransferases.Bacterial Proteins: Proteins found in any species of bacterium.Bacteroides Infections: Infections with bacteria of the genus BACTEROIDES.Cefotaxime: Semisynthetic broad-spectrum cephalosporin.Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.Bacterial Infections: Infections by bacteria, general or unspecified.Enterobacter: Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.Drug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.Isoelectric Focusing: Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point.Penicillins: A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)
For treatment of latent TB infection (LTBI) only *^ For use only in combination with meropenem or imipenem/cilastatin ... Medicines for ectoparasitic infections. *Ivermectin. Antimigraine medicines. For treatment of acute attack. * ... To be used for the treatment of Trypanosoma brucei gambiense infection *^ To be used for the treatment of the initial phase of ... To be used for the treatment of T. b. gambiense infection *^ Only to be used in combination with eflornithine, for the ...
C. histolyticum is also susceptible to metronidazole and imipenem. However, advanced gas gangrene infections caused by C. ... If not controlled, the infection can result in systemic toxemia, multiorgan failure, and even death. Further, this infection ... Anaerobic blood cultures are necessary for identification of C. histolyticum infection. For most infections, clindamycin and ... However, there have been few cases of human infection by this species. From 1984 to 2004, only one case of C. histolyticum ...
This includes joint infections, intra-abdominal infections, meningitis, pneumonia, sepsis, and urinary tract infections. It ... for meningitis caused by Acetobacter, as an adjunct to imipenem or colistin ... Mycobacterial infections, including as a second-line agent for active tuberculosis. It is also used for infections by ... Skin and suture-site infections. *Urinary tract infections that are caused by bacteria resistant to less toxic drugs (often ...
Doripenem, imipenem, and meropenem are recommended for high-risk community-acquired abdominal infections and for abdominal ... coli infections. The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious ... and somewhat more potent against gram-negative infections. Unlike imipenem, which produced an unacceptable rate of seizures in ... "Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections". Curr Med Res Opin. ...
... is an antiemetic often given to offset the nausea and vomiting that are a common side effect of Imipenem. Severe infections ... This does not mean, however, that they will not cause an infection in the right circumstances. M. fortuitum infection can be a ... Postoperative sternal wound infections, endocarditis, meningitis, and osteomyelitis. Has produced postoperative infections ... joint infections and infections of the eye after trauma. Mycobacterium fortuitum has a worldwide distribution and can be found ...
Susceptible to amikacin, imipenem, cefoxitin, clarithromycin and ciprofloxacin. Resistant to isoniazid and rifampin. ... Posttraumatic skin infections, catheter sepsis and respiratory isolates without clinical significance except in ...
One such derivative - imipenem - was formulated in 1985. Imipenem, an N-formimidoyl derivative of thienamycin, is rapidly ... Consequently, it is impractical for the clinical treatment of bacterial infections, so stable derivatives were created for ... To prevent its rapid degradation, imipenem is normally coadministered with cilastatin, an inhibitor of this enzyme. Nicolaou, K ... a guide to their use in serious infection". Int. J. Antimicrob. Agents. 11 (2): 93-100. doi:10.1016/S0924-8579(98)00094-6. PMID ...
In 1985 Merck received approval for imipenem, the first member of the carbapenem class of antibiotics. Antibiotics of the ... Isentress (raltegravir) is a human immunodeficiency virus integrase inhibitor for the treatment of HIV infection. It is the ... ISBN 978 184129 012 6. "Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by ... Adverse effects include increased risk of infection and certain cancers. Gardasil (recombinant human papilloma virus vaccine) ...
Amikacin Amphotericin B Ceftobiprole Ceftaroline Carbapenems (such as imipenem/cilastatin) - used as drug of last resort for a ... Used to treat XDR Acinetobacter baumannii infections. Tolcapone - used in patients with Parkinson's disease who are not ... its usefulness only as an injectable and potency in treatment of infection with multiple drug-resistant organisms has caused a ... variety of different bacterial infections. Clomethiazole - a sedative/hypnotic agent used in the treatment of alcohol ...
... canimorsus Infections in Human: Review of the Literature and Cases Report. European Journal of Epidemiology 12(5 ... The imipenem/cilastatin, clindamycin, or combinations containing an inhibitor of beta-lactamases (i.e. Augmentin, Unasyn) are ... Treatment of infectionsEdit. The high frequency of strains producing beta-lactamase limit the use of single beta-lactam ... involvement in bone infections: a review. Int J Antimicrob Agents. 2013 Jun;41(6):509-15. ...
It is approved for complicated skin and skin structure infections, complicated intra-abdominal infections and bacterial ... The overall spectrum is similar to that of imipenem, although meropenem is more active against Enterobacteriaceae and less ... intra-abdominal infection, pneumonia, sepsis, and anthrax. It is given by injection into a vein. ... is a broad-spectrum antibiotic used to treat a variety of bacterial infections. Some of these include meningitis, ...
It has been described as a cause of infection in gibbons. Infection caused by C. violaceum is rare, therefore there are no ... although carbapenems like meropenem or imipenem may possibly work. Though the bacteria is reported to be resistant to first ... The disease usually starts as a limited infection of the skin at the point of entry of the bacteria, which progresses to ... For theoretical reasons, infection would not be expected to respond to penicillins, cephalosporins, or aztreonam, ...
... rifampin and imipenem for treating a bla VIM-1 metallo-beta-lactamase-producing Enterobacter cloacae disseminated infection in ... Outbreak of infection caused by Enterobacter cloacae producing the novel VEB-3 beta-lactamase in China. J. Clin. Microbiol.43(2 ... Infections with VIM-1 metallo-beta-lactamase-producing Enterobacter cloacae and their correlation with clinical outcome. J. ... Nosocomial bloodstream infections in us hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. ...
For infections caused by ESBL-producing Escherichia coli or Klebsiella species, treatment with imipenem or meropenem has been ... imipenem produced the better outcome There have been few clinical studies to define the optimal therapy for infections caused ... CTX-M-15-positive E. coli are a cause of community-acquired urinary infections in the UK, and tend to be resistant to all oral ... Moreover, one should suspect these strains when treatment with these agents for Gram-negative infections fails despite reported ...
It can cause various other infections, including skin and wound infections, bacteremia, and meningitis, but A. lwoffi is mostly ... Among one set of isolates from Walter Reed Army Medical Center, 13 (35%) were susceptible to imipenem only, and two (4%) were ... urinary tract infections (UTIs), secondary meningitis, infective endocarditis, and wound and burn infections. In particular, A ... Wood GC, Hanes SD, Croce MA, Fabian TC, Bougher BA (2002). "Comparison of ampicillin-sulbactam and imipenem-cilastatin for the ...
... and to intravenous imipenem and cilastatian to treat complicated intra-abdominal infections. Tigecycline is active against many ... The drug is licensed for the treatment of skin and soft tissue infections as well as intra-abdominal infections. The European ... Tigecycline is used to treat different kinds of bacterial infections, including complicated skin and structure infections, ... Tigecycline is an antibiotic used to treat a number of bacterial infections. It is a glycylcycline that is administered ...
Unlike imipenem and meropenem, ertapenem is highly protein-bound, which results in a longer half-life (4 hours). Ertapenem is ... It should not be used as empirical treatment for hospital-acquired infections because of its lack of activity against ... Other members of the carbapenem group (imipenem, doripenem, and meropenem) are broadly active antibacterials that are used for ... In 2006, Ertapenem became approved for pediatric use in certain infections. Ertapenem is not recommended for children under 3 ...
infections". Ann Pharmacother. 41 (10): 1694-9. doi:10.1345/aph.1K196. PMID 17785610. Chiba K, Hoshino Y, Ishino K, Kogure T, ... Minocycline is usually substituted when a sulfa cannot be given; high-dose imipenem and amikacin have also been used in severe ... Most Nocardia infections are acquired by inhalation of the bacteria or through traumatic introduction. Nocardia colonies have a ... It is not uncommon for this infection to spread to the pleura or chest wall. Pre-existing pulmonary disease, especially ...
involvement in bone infections: a review. Int J Antimicrob Agents. 2013 Jun;41(6):509-15. Rogers MB, Parker AC, Smith CJ. 1993 ... The imipenem/cilastatin, clindamycin or combinations containing an inhibitor of beta-lactamases (i.e. Augmentin, Unasyn) are ... Capnocytophaga canimorsus Infections in Human: Review of the Literature and Cases Report. European Journal of Epidemiology 12 ( ... This bacterium is involved in different types of infections the severity of which depends on the immune status of the patient. ...
It is usually caused by a bacterial infection, rather than a virus. HAP is the second most common nosocomial infection (after ... cefepime, ceftazidime, imipenem, meropenem or piperacillin-tazobactam; plus ciprofloxacin, levofloxacin, amikacin, gentamicin, ... It is the most common cause of death among nosocomial infections and is the primary cause of death in intensive care units. HAP ... Pneumonia that starts in the hospital tends to be more serious than other lung infections because: people in the hospital are ...
... thus play a key role in the treatment of infections not readily treated with other antibiotics. Imipenem was patented in 1975. ... Not many species are resistant to imipenem except Pseudomonas aeruginosa (Oman) and Stenotrophomonas maltophilia. Imipenem is ... Imipenem has a broad spectrum of activity against aerobic and anaerobic, Gram-positive and Gram-negative bacteria. It is ... At high doses, imipenem is seizurogenic. U.S. Patent 4,194,047 Clissold, SP; Todd, PA; Campoli-Richards, DM ( ...
It is part of the normal flora of the human colon and is generally commensal, but can cause infection if displaced into the ... "Penicillin-binding proteins of Bacteroides fragilis and their role in the resistance to imipenem of clinical isolates". Journal ... Bacteroides infections at eMedicine Brook I (June 2010). "The role of anaerobic bacteria in bacteremia". Anaerobe. 16 (3): 183- ... ISBN 0-443-06643-4. Brook I (December 2007). "Treatment of anaerobic infection". Expert Rev Anti Infect Ther. 5 (6): 991-1006. ...
... is used for lower respiratory tract infections, urinary tract infections, intra-abdominal infections, ... bone and joint infections, skin and skin structure infections, endocarditis and polymicrobic infections. It is a broad-spectrum ... Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. ... Imipenem/cilastatin has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by ...
On the rare occasions where infection is superficial and limited (for example, ear infections or nail infections), topical ... carbapenems (meropenem, imipenem, doripenem, but not ertapenem) polymyxins (polymyxin B and colistin) monobactams (aztreonam) ... and also causes other blood infections. It is the most common cause of infections of burn injuries and of the outer ear (otitis ... Cystic fibrosis patients are also predisposed to P. aeruginosa infection of the lungs. P. aeruginosa may also be a common cause ...
... and urinary tract infections). Extrapancreatic infections are associated with an increase in mortality. When an infection is ... An early randomized controlled trial of imipenem 0.5 gram intravenously every eight hours for two weeks showed a reduction in ... The most common cause of death in acute pancreatitis is secondary infection. Infection is diagnosed based on 2 criteria Gas ... Up to 20 percent of patients with acute pancreatitis develop an extrapancreatic infection (e.g., bloodstream infections, ...
... , also known as penicillin G, is an antibiotic used to treat a number of bacterial infections. This includes ... Imipenem/cilastatin#. *Imipenem/cilastatin/relebactam. *Ampicillin/flucloxacillin. *Ampicillin/sulbactam (Sultamicillin). * ...
Infection due to a bacteria that is know to be resistant to levofloxacin or imipenem or certain other drugs that may be used ... Respiratory Tract Infections. Levofloxacin. Ofloxacin. Imipenem. Cilastatin. Anti-Infective Agents, Urinary. Anti-Infective ... The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment ... Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a ...
Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach ... Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. ... Imipenem and cilastatin is usually given as long as needed until your infection has cleared or you have been symptom-free for ... Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach ...
Manufacturer & Supplier of Imipenem Cilastatin For Injection Usp 250 Mg based in Bengaluru, India ... This Imipenem Cilastatin For Injection Usp 250 Mg eliminates bacteria that cause various types of infections, including ... Over the years, we have been renowned as the topmost manufacturer, best known for supplying an extensive range of Imipenem ... pneumonia and gynecological, bone, joint, urinary tract, skin, stomach, blood, and heart valve infections. ...
The genome of the imipenem-susceptible isolate G7 was sequenced to closure and used as a reference for comparative genomics. ... To do this, series of clinical isolates have been periodically collected from two patients during chemotherapy with imipenem. ... Infections caused by multidrug resistant (MDR) bacteria are a major concern worldwide. Changes in membrane permeability, ... Enterobacter infections Is the Subject Area "Enterobacter infections" applicable to this article? Yes. No. ...
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative ... complicated urinary tract infection. cefiderocol. acute uncomplicated pyelonephritis. Gram-negative pathogens. imipenem/ ... A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections (APEKS- ... Active Comparator: Imipenem/cilastatin Drug: Imipenem/cilastatin 1000 mg intravenously every 8 hours for a period of 7 to 14 ...
Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin preparation information is provided by Wedgewood Pharmacy. ... Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin Otic Suspension may be prescribed for Infection-Bacterial. ... Infection-Bacterial. The dosage form available for Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin is Otic Suspension ... May be Prescribed For: Infection-Bacterial. Order now.. For veterinary professionals: Order from our 40,000-preparation ...
Imipenem-nonsusceptible infections.At baseline, 36 subjects (13%) in the MITT population had Gram-negative infections that were ... In vivo infection models with imipenem-resistant P. aeruginosa and K. pneumoniae show that REL given with imipenem-cilastatin ( ... including 7 subjects with imipenem-nonsusceptible Gram-negative infections that were susceptible to REL plus imipenem. Most of ... Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. ...
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. ... Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection ... Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection ... Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection ...
... of the 99 IMI patients had a single site of infection whereas the remainder had two or more sites of infection. Infections of ... Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre ... Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre ... have been compared with imipenem/cilastatin (IMI: 1 g every 8 h, iv) in patients with serious bacterial infections at one or ...
High incidence of MBL-mediated imipenem resistance among Pseudomonas aeruginosa from surgical site infections in Egypt * Marian ... Results: Out of 200 pus samples collected from surgical site infections, P. aeruginosa had the prevalence rate of 35%. Imipenem ... the incidence of imipenem-resistant Pseudomonas aeruginosa infection of surgical wounds particularly that mediated by MBL ... High incidence of MBL-mediated imipenem resistance among Pseudomonas aeruginosa from surgical site infections in Egypt. J ...
Drugs to treat infections. These drugs can lower the levels of valproic acid in your body. This means that it wont work as ... imipenem. *meropenem. Pain drugs. Taking valproic acid and aspirin can increase levels of aspirin in your body. This can cause ...
... intra-abdominal infections, septic arthritis, osteomyelitis, CNS infections, and ophthalmic infections. Enterobacter infections ... lower respiratory tract infections, skin and soft-tissue infections, urinary tract infections (UTIs), endocarditis, ... Alternative to imipenem for severe Enterobacter infections. Carbapenem of choice for meningitis and for patients at risk for ... Used for pseudomonal infections and infections due to multidrug-resistant gram-negative organisms. ...
Imipenem dosage information for adults and children. Includes dosages for Bacterial Infection, Urinary Tract Infection, ... Usual Adult Dose for Joint Infection. If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem ... Usual Adult Dose for Bacterial Infection. If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem ... Usual Adult Dose for Pelvic Infections. If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem ...
Community-onset urinary tract infections: a population-based assessment. Infection 35:150-153 [PubMed] ... Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection ... These results suggest that amoxicillin-clavulanate could be an alternative to imipenem treatment of infections caused by ESBL- ... the results suggest that amoxicillin-clavulanate could be an alternative to imipenem treatment of infections caused by ESBL- ...
Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre ...
BACKGROUND: The bactericidal exposures necessary for positive clinical outcomes among skin and soft tissue infections are ... RESULTS: Imipenem-cilastatin, meropenem, and piperacillin-tazobactam 3.375 g q6h achieved greater than 90% likelihood of ... Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft ... CONCLUSIONS: When the incidence of MRSA is low, imipenem-cilastatin, meropenem and piperacillin-tazobactam 3.375 g q6h would be ...
... an antibiotic often reserved as a last-line treatment for infections. ... This article explores both national and regional trends in rates of Acinetobacter resistance to imipenem, ... Eight out of nine U.S. regions showed decreased imipenem susceptibility.. *Eight regions had imipenem susceptibility of less ... This article explores both national and regional trends in rates of Acinetobacter resistance to imipenem, an antibiotic often ...
All ribotype 017 isolates carried an extra penicillin-binding protein gene, pbp5, and the imipenem-resistant isolates had ... These clones could disseminate and contribute to imipenem resistance. ... We describe imipenem-resistant and imipenem-susceptible clinical isolates of Clostridium difficile ribotype 017 in Portugal. ... Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. DOIPubMed ...
A drug used to treat or prevent bacterial infections.. allergen A chemical compound, or part thereof, which causes the onset of ... imipenem (CHEBI:471744) is a β-lactam antibiotic allergen (CHEBI:88225) imipenem (CHEBI:471744) is a carbapenems (CHEBI:46633) ... imipenem (CHEBI:471744) has role antibacterial drug (CHEBI:36047) ...
It is used to treat bacterial infections.. What do I need to tell the doctor BEFORE my child takes this drug?. *If your child ... Imipenem and Cilastatin for Injection; Imipenem and Cilastatin for Injection, USP; Primaxin; RAN-Imipenem-Cilastatin ... A second infection may happen.. *Severe and sometimes deadly allergic side effects have rarely happened with drugs like this ... Imipenem and Cilastatin - Last updated on July 5, 2020. ©2020 Memorial Sloan Kettering Cancer Center. ...
Professional guide for Imipenem and Cilastatin. Includes: pharmacology, pharmacokinetics, contraindications, interactions, ... Dosage based on imipenem content:. Non-CNS infections: IV: Infants ≥3 months, Children, and Adolescents: 15 to 25 mg/kg every 6 ... Bone and joint infections: Treatment of bone and joint infections caused by E. faecalis, S. aureus (penicillinase-producing), ... carbapenems meropenem, ertapenem, Invanz, cilastatin / imipenem, Merrem, Primaxin IV. Urinary Tract Infection ciprofloxacin, ...
Imipenem and meropenem are carbapenem antimicrobial agents used to treat a variety of serious infections when an organism is ... Types of Infectionsplus icon *Central Line-associated Bloodstream Infectionsplus icon *Resources for Patients & Providers ... Imipenem degrades easily. Studies suggest meropenem may be more stable than imipenem. However, for either antimicrobial agent, ... Infection Control Assessment Tools. *Environmental Cleaning in Resource-Limited Settingsplus icon *Key Definitions & ...
Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J ... Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis. ... The mortality rate for these serious infections due to AB varies by geography and type of infection, but is roughly 30-75%. ... AB primarily causes nosocomial infections, although community-acquired infections have been reported  and are increasing ...
CilastatinPneumoniaMeropenemIntra-abdominalBacteriaRelebactamSusceptibilityResistance to imipenemCarbapenemCarbapenemsCefepimeNosocomialIntravenousRenalErtapenemInjecting imipenem and cilastatinLower RespiInjectionAnaerobicCephalosporinsEpidemiologyPiperacillin-tazobactamClinicalMedicationPrevalenceCilastatin sodiumEnterobacterOrganismsMortalityAntibacterialOpportunistic
- This multicenter, open-label study evaluates the safety and effectiveness of levofloxacin as compared with imipenem/cilastatin, another type of antibiotic treatment, in patients with pneumonia acquired in the hospital. (clinicaltrials.gov)
- Patients receive treatment for a total of 7-15 days, initially with levofloxacin or imipenem/cilastatin, administered slowly through a vein. (clinicaltrials.gov)
- If patients respond positively to either drug, treatment may be changed to levofloxacin or ciprofloxacin (if initially treated with imipenem/cilastatin), to be taken by mouth. (clinicaltrials.gov)
- The study hypothesis is that levofloxacin is at least as effective as imipenem/cilastatin in treating hospital-acquired pneumonia and is generally well-tolerated. (clinicaltrials.gov)
- Levofloxacin 750 mg administered through a vein once daily or imipenem/cilastatin 500mg-1 gram every 6-8 hours. (clinicaltrials.gov)
- Despite advances in prevention and treatment, hospital-acquired pneumonia remains a significant problem as the second most common infection acquired in the hospital and the most deadly (20%-50% of patients who acquire pneumonia while in the hospital die from complications of pneumonia). (clinicaltrials.gov)
- In an open randomised multicentre trial the efficacy (clinical and bacteriological) and safety of empirical monotherapy with meropenem (MEM: 1 g every 8 h, iv) have been compared with imipenem/cilastatin (IMI: 1 g every 8 h, iv) in patients with serious bacterial infections at one or more of the following sites: systemic, intra-abdominal and lower respiratory tract infections. (biomedcentral.com)
- Imipenem-cilastatin and meropenem are used most often. (medscape.com)
- In August 2017, meropenem/vaborbactam (Vabomere) was approved for complicated urinary tract infections (cUTIs), including pyelonephritis, caused by susceptible Enterobacteriaceae: E coli, K pneumoniae, and E cloacae species complex. (medscape.com)
- MIC) in serum and blister fluid was calculated for 5,000 simulated patients receiving imipenem-cilastatin 0.5 g q8h, meropenem 0.5 g q8h, piperacillin-tazobactam 3.375 g q6h, and piperacillin-tazobactam 4.5 g q8h. (qxmd.com)
- When the incidence of MRSA is low, imipenem-cilastatin, meropenem and piperacillin-tazobactam 3.375 g q6h would be optimal choices for the empiric treatment of complicated skin and soft tissue infections among the regimens studied. (qxmd.com)
- The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation]. (qxmd.com)
- Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. (qxmd.com)
- Why is imipenem and meropenem resistance important? (cdc.gov)
- Imipenem and meropenem are carbapenem antimicrobial agents used to treat a variety of serious infections when an organism is resistant to the primary agent of choice. (cdc.gov)
- How much resistance to imipenem or meropenem occurs in clinical isolates? (cdc.gov)
- What Gram-negative organisms are resistant to imipenem and/or meropenem? (cdc.gov)
- Studies suggest meropenem may be more stable than imipenem. (cdc.gov)
- Meropenem is slightly more active than imipenem against Gram-negative organisms. (cdc.gov)
- The carbapenems imipenem and meropenem play an important role in the empirical anti-infective treatment of critically ill patients. (cdc.gov)
- Imipenem-resistant strains were further tested for meropenem susceptibility. (cdc.gov)
- We conclude that imipenem, but not meropenem, resistance is frequent in Hi. (cdc.gov)
- All isolates were found to be resistant to imipenem and meropenem. (asm.org)
- The minimum inhibitory concentrations were determined of imipenem, meropenem and ertapenem for Klebsiella isolates. (who.int)
- Meropenem-Vaborbactam (MV) Compared With Piperacillin-Tazobactam (PT) in the Treatment of Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in a Phase 3 Randomized, Double-Blind, Double-Dummy Trial (TANGO 1). (medscape.com)
- Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. (medscape.com)
- Imipenem, meropenem, and cefepime were the most effective agents against gram-negative organisms. (medindia.net)
- In this multicenter, double-blind, controlled trial (NCT01506271), subjects who were ≥18 years of age with complicated intra-abdominal infection were randomly assigned (1:1:1) to receive 250 mg REL, 125 mg REL, or placebo, each given intravenously (i.v.) with 500 mg imipenem-cilastatin (IMI) every 6 h (q6h) for 4 to 14 days. (asm.org)
- The clinically satisfactory response rates for the specific sites were 79.4% (MEM)and 75.0% (IMI) for the lower respiratory tract infections, 96.0% (MEM) and 83.9% (IMI) for the intra-abdominal infections and 85.7% (MEM) and 66.7% (IMI) for the systemic infections. (biomedcentral.com)
- Piperacillin-tazobactam and carbapenems are among the recommended empirical treatments for health care-associated complicated intra-abdominal infections. (pubmedcentralcanada.ca)
- Escherichia coli is a common etiologic agent of intra-abdominal infections (IAI) ( 1 ) associated with a heavy bacterial burden ( 2 ) and of urinary tract infections and bacteremia ( 3 - 5 ), among others. (pubmedcentralcanada.ca)
- or = 1.0 mg/L. Garenoxacin may be a valuable surgical anti-infective for treatment of serious head and neck, soft tissue, intra-abdominal and diabetic foot infections. (nih.gov)
- A blood culture positive for Enterococcus species in a patient with a polymicrobial infection from an intra-abdominal source indicates the need for antimicrobial therapy, including activity against enterococci. (medscape.com)
- In elderly and/or immunocompromised patients, an intra-abdominal source of infection may manifest as minimal localizing signs or symptoms. (medscape.com)
- A non-β-lactam β-lactamase inhibitor used in combination with ceftazidime for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and hospital or ventilator-acquired pneumonia. (drugbank.ca)
- An antibiotic of the penem class used to treat complicated intra-abdominal and urinary tract infections. (drugbank.ca)
- Intra-abdominal infection is fairly common in both the community and hospitalized settings, carries significant associated morbidity and mortality, and is second only to respiratory tract infection as a cause of sepsis, severe sepsis and septic shock. (clinicaladvisor.com)
- Intra-abdominal infection encompasses a diverse spectrum of processes (sterile inflammation, obstruction, perforation, necrosis, primary contamination from trauma or surgery, failed immune system or recent antimicrobial therapy) at a broad range of sites (peritoneal space, retroperitoneum, any abdominal viscous). (clinicaladvisor.com)
- Cognitive recognition (i.e. consider the diagnosis of intra-abdominal infection). (clinicaladvisor.com)
- Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options. (fda.gov)
- Complicated intra-abdominal infections (adult and pediatric patients). (nih.gov)
- 1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients. (nih.gov)
- 4-MRGN bacteria principally cause urinary tract infections, nosocomial pneumonia, (soft) tissue infections, intra-abdominal infections, and infections of the bloodstream. (aerzteblatt.de)
- Considering taking medication to treat infection+of+the+blood+caused+by+the+bacteria+anthrax? (webmd.com)
- Below is a list of common medications used to treat or reduce the symptoms of infection+of+the+blood+caused+by+the+bacteria+anthrax. (webmd.com)
- Anyone who has contact with a surface, object, animal, or another person that is infected with or has been exposed to ESBL-producing bacteria can spread the infection. (medicalnewstoday.com)
- According to a 2015 study , most people infected with ESBL-producing bacteria had been hospitalized for an average of between 11 and 64 days before developing the infection. (medicalnewstoday.com)
- Some people who do not develop an infection or show symptoms can act as carriers, spreading the infectious bacteria without knowing it. (medicalnewstoday.com)
- Most ESBL-producing bacteria are called Enterobacteriaceae , a family of bacteria that normally lives in the gastrointestinal tract without causing infection. (medicalnewstoday.com)
- Imipenem and cilastatin injection is used to treat certain serious infections that are caused by bacteria, including endocarditis (infection of the heart lining and valves) and respiratory tract (including pneumonia), urinary tract, abdominal (stomach area), gynecological, blood, skin, bone, and joint infections. (medlineplus.gov)
- If you stop using imipenem and cilastatin injection too soon or if you skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (medlineplus.gov)
- Imipenem is a broad spectrum antibiotic produced by the bacteria Streptomyces cattleya. (wikipedia.org)
- A fourth-generation cephalosporin antibiotic used in the treatment of various bacterial infections caused by susceptible bacteria, such as pneumonia, urinary tract infections, and skin infections. (drugbank.ca)
- It works by preventing bacteria from destroying imipenem. (medlineplus.gov)
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (rxlist.com)
- Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. (nih.gov)
- For the treatment of bacterial infections caused by susceptible bacteria. (drugbank.ca)
- Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. (drugbank.ca)
- Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. (drugbank.ca)
- This strain of the bacteria can lead to serious and often life-threatening lung infections seen in children with cystic fibrosis or bronchiectasis, the researchers explained. (news-medical.net)
- The team explained that Mycobacterium abscessus infections in these patients earlier necessitated not only hospitalization but also removed the patients from lung transplant wait lists as surgery could not be performed if a person was infected with this bacteria. (news-medical.net)
- Approximately 50% of these infections are due to gram-negative bacteria, and slightly less than 50% are caused by gram-positive bacteria. (atsu.edu)
- Imipenem is an antibiotic that fights bacteria. (wellspan.org)
- Imipenem kills or stops the growth of bacteria that cause severe infections. (prescriptiongiant.com)
- Bacteria cause most urinary tract infections and enter through the urethra. (healthhype.com)
- Most urinary tract infections are due to bacteria. (healthhype.com)
- Although there are various different types of bacteria that can cause urinary tract infections, it is the bacteria from the bowels especially Escherichia coli ( E.coli ) that are mainly responsible for UTIs. (healthhype.com)
- DWB's analysis found that drug-resistant bacteria caused 69 percent of all infections in Syrian patients and were present in 55 percent of Iraqi patients with bone infections. (theatlantic.com)
- As the carbapenems have been the gold standard to date for the systemic treatment of serious infections with Gram-negative bacteria, carbapenem resistance presents new and difficult challenges in therapeutic decision-making, particularly because of the high frequency of co-resistance. (aerzteblatt.de)
- Relebactam (REL [MK- is a novel class A/C β-lactamase inhibitor intended for use with imipenem for the treatment of Gram-negative bacterial infections. (asm.org)
- Imipenem, cilastatin, and relebactam injection is used to treat adults with certain serious urinary tract infections including kidney infections, and certain serious abdominal (stomach) infections when there are few or no other treatment options. (medlineplus.gov)
- Imipenem, cilastatin, and relebactam injection may cause side effects. (medlineplus.gov)
- Ceftazidime-avibactam and ceftolozane-tazobactam are currently FDA-approved and available for use, while cefiderocol and imipenem-cilastatin/relebactam are in development. (springer.com)
- Trials are ongoing for cefiderocol and imipenem-cilastatin/relebactam and early results appear promising. (springer.com)
- The team of researchers used a cocktail of three medications - amoxicillin and imipenem-relebactam for treatment of infections in patients with cystic fibrosis. (news-medical.net)
- Samples were collected from these patients before they were administered a regimen of medications containing amoxicillin-imipenem-relebactam. (news-medical.net)
- Because amoxicillin is already widely available and imipenem-relebactam has just been approved for use by the Food and Drug Administration (FDA) in the US, these drugs are already available to clinicians. (news-medical.net)
- Today, the U.S. Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older. (fda.gov)
- Recarbrio is a combination of imipenem-cilastatin and relebactam. (fda.gov)
- The bactericidal exposures necessary for positive clinical outcomes among skin and soft tissue infections are largely dependent on interpatient pharmacokinetic variability and pathogen drug susceptibility. (qxmd.com)
- Eight out of nine U.S. regions showed decreased imipenem susceptibility. (rwjf.org)
- Eight regions had imipenem susceptibility of less than 85 percent by 2006. (rwjf.org)
- Overall, the East South Central region was the only region not showing a significant decrease in imipenem susceptibility. (rwjf.org)
- There was no significant difference (P = 0.97) in the survival rates comparing the two treatment regimens irrespective of the ET positivity or the susceptibility to moxifloxacin or imipenem of the infective B. fragilis strain. (nih.gov)
- Awareness of the causative organisms in diabetic foot infections and their antimicrobial susceptibility pattern is essential for the institution of antimicrobial therapy. (medindia.net)
- Indicated for complicated urinary tract infections (cUTI) caused by carbapenem-resistant Enterobacteriaceae (CRE). (medscape.com)
- A carbapenem antibiotic normally administered with cilastatin to treat a variety of infections. (drugbank.ca)
- Polymyxin B is one of the last resort option for carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection in China. (scielo.br)
- Rates of colonization and infection with carbapenem-resistant Gram-negative pathogens are on the rise, particularly in southeastern European countries, and this is increasingly true in Germany as well. (aerzteblatt.de)
- The treatment of severe infection with carbapenem-resistant pathogens should be individualized and carried out in an interdisciplinary framework, in consideration of antibiotic pharmacokinetics and pharmacodynamics in each case. (aerzteblatt.de)
- The antimicrobials most commonly indicated in Enterobacter infections include carbapenems, fourth-generation cephalosporins, aminoglycosides, fluoroquinolones, and TMP-SMZ. (medscape.com)
- Carbapenems also are used to treat nosocomial and mixed bacterial infections. (cdc.gov)
- We provide prevalence data for resistance to carbapenems from laboratory surveillance of invasive Hi infections in Germany in 2016. (cdc.gov)
- Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. (drugbank.ca)
- M. fortuitum infection can be a nosocomial (hospital acquired) disease. (wikipedia.org)
- Reichert F, Piening B, Geffers C, Gastmeier P, Bührer C, Schwab F. Pathogen-Specific Clustering of Nosocomial Blood Stream Infections in Very Preterm Infants. (medscape.com)
- A prediction tool for nosocomial multi-drug Resistant Gram-Negative Bacilli infections in critically ill patients - prospective observational study. (nih.gov)
- The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study. (nih.gov)
- Limited resources in these countries impose strict monitoring of nosocomial infections, in particular CRI. (fichier-pdf.fr)
- To determine the efficacy and safety of intravenous S-649266 in hospitalized adults with complicated urinary tract infections caused by Gram-negative pathogens. (clinicaltrials.gov)
- The purpose of this study is to determine the efficacy and safety of intravenous S 649266 versus intravenous imipenem/cilastatin in hospitalized adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis caused by Gram-negative pathogens. (clinicaltrials.gov)
- Twenty-four hours post-infection, intravenous therapy with either moxifloxacin (2.0 mg twice a day) or imipenem (2.4 mg three times a day) was started and continued for 3 days. (nih.gov)
- Examination of all intravenous catheters for evidence of exit site or tunnel infection. (clinicaladvisor.com)
- That antibiotic is imipenem, a broad-spectrum intravenous medication. (theatlantic.com)
- Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules. (drugs.com)
- A CT scan of the abdomen is indicated if symptoms or signs indicate a renal or gastrointestinal source of infection or if no clear focus of infection is evident elsewhere. (medscape.com)
- A renal dehydropeptidase inhibitor used to prevent degradation of imipenem. (drugbank.ca)
- Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation. (drugbank.ca)
- Imipenem and cilastatin injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) or intramuscularly (into a muscle). (medlineplus.gov)
- Your doctor will tell you how long to use imipenem and cilastatin injection. (medlineplus.gov)
- You may receive imipenem and cilastatin injection in a hospital, or you may administer the medication at home. (medlineplus.gov)
- If you are using imipenem and cilastatin injection at home, use it at around the same times every day. (medlineplus.gov)
- Use imipenem and cilastatin injection exactly as directed. (medlineplus.gov)
- If you will be using imipenem and cilastatin injection at home, your healthcare provider will show you how to use the medication. (medlineplus.gov)
- You should begin to feel better during the first few days of treatment with imipenem and cilastatin injection. (medlineplus.gov)
- Use imipenem and cilastatin injection until you finish the prescription, even if you feel better. (medlineplus.gov)
- or any of the ingredients in imipenem and cilastatin injection. (medlineplus.gov)
- Other possible sources of M. fortuitum infection include implanted devices such as catheters, injection site abscesses, and contaminated endoscopes. (wikipedia.org)
- The red area often occurs at the infection point, which may include surgical sites, a cut, scratch, bruise, boil, site of medication or drug injection, or any small injury that could have occurred during daily life. (rarediseases.org)
- What is imipenem/cilastatin injection? (prescriptiongiant.com)
- Imipenem/cilastatin is for injection into a muscle or infusion into a vein. (prescriptiongiant.com)
- Clinical cure in clinical outcomes (resolution of the signs and symptoms of complicated urinary tract infection [cUTI] or return to pre-infection baseline if known). (clinicaltrials.gov)
- A clinical trial failed to demonstrate non-inferiority of TYGACIL for treatment of diabetic foot infections. (rxlist.com)
- Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. (drugbank.ca)
- Prevalence and spread of extended-spectrum β -lactamase-producing Enterobacteriaceae in Europe," Clinical Microbiology and Infection , vol. 14, no. 1, pp. 144-153, 2008. (hindawi.com)
- J. Rodríguez-Baño and M. D. Ngugro, "Extended-spectrum β -lactamases in ambulatory care: a clinical perspective," Clinical Microbiology and Infection , vol. 14, no. 1, pp. 104-110, 2008. (hindawi.com)
- Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues," Clinical Microbiology and Infection , vol. 16, no. 2, pp. 112-122, 2010. (hindawi.com)
- Clinical cure: complete resolution of infection symptoms (bacteremia) present at the day on which the assessment is done and patient is alive. (clinicaltrials.gov)
- Has slightly increased activity against gram-negative organisms and slightly decreased activity against staphylococci and streptococci compared to imipenem. (medscape.com)
- 1. Recite the most likely causes of sepsis based on the knowledge of the initial site of infection and where these organisms usually come from (sources of infection). (atsu.edu)
- Bloodstream infection (BSI) is very common and is associated with high morbidity and mortality worldwide. (springer.com)
- Bloodstream infection (BSI) caused by CRKP is a more serious situation due to ineffective antibacterials and high mortality. (scielo.br)
- Such infections are associated with serious morbidity and mortality and with increased health care costs . (fichier-pdf.fr)
- The neutropenic patient with fever is at high risk for mortality from infection acutely. (clinicaladvisor.com)
- This designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. (fda.gov)
- An antibacterial peptide developed by Laszlo Otvos, a research professor of biology in Temple's College of Science and Technology, looks to be a highly-effective therapy against infections in burn or blast wounds suffered by soldiers. (bio-medicine.org)